<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01532297</url>
  </required_header>
  <id_info>
    <org_study_id>HD-CiDi-01-D</org_study_id>
    <secondary_id>There is no secondary ID</secondary_id>
    <nct_id>NCT01532297</nct_id>
  </id_info>
  <brief_title>Application of Citrate Dialysate in Chronic Haemodialysis</brief_title>
  <official_title>Application of Citrate Dialysate in Chronic Haemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study investigating the safety and efficacy of the citrate dialysis solution compared to
      standard acetate dialysis solution. Use of citrate dialysis solution is not associated with a
      clinically relevant development of adverse events. It is hypothesized that citrate dialysate
      may provide a local anticoagulation effect in the dialyser improving removal of uremic
      toxins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that citrate dialysate may provide a local anticoagulation effect in the
      dialyser improving removal of uremic toxins. Study investigating the safety and efficacy of
      the citrate dialysis solution compared to standard acetate dialysis solution. Use of citrate
      dialysis solution is not associated with a clinically relevant development of adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of clinically relevant calcium disturbances</measure>
    <time_frame>patients are followed for 8 weeks</time_frame>
    <description>during or post-dialysis hypocalcaemia with ionized Ca ≤ 0.9 mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinically relevant acid-base disturbances</measure>
    <time_frame>patients are followed for 8 weeks</time_frame>
    <description>during or post-dialysis severe alkalosis with pH ≥ 7.55</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically relevant acid-base disturbances</measure>
    <time_frame>patients are followed for 8 weeks</time_frame>
    <description>post-dialysis bicarbonate concentration ≥ 32 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically relevant acid-base disturbances</measure>
    <time_frame>patients are followed for 8 weeks</time_frame>
    <description>pre-treatment bicarbonate concentration ≥ 27 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically relevant intradialytic complications (adverse events)</measure>
    <time_frame>patients are followed for 8 weeks</time_frame>
    <description>related to citrate dialysate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically relevant adverse events</measure>
    <time_frame>patients are followed for 8 weeks</time_frame>
    <description>related to citrate</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Chronic Renal Disease</condition>
  <arm_group>
    <arm_group_label>HD treated with standard dialysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>post-dilution oHDF with standard dialysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-dilution oHDF with citrate dialysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HD treated with citrate dialysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>post-dilution oHDF with citrate dialysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-dilution oHDF with standard dialysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Citrate dialysate (CiDi)</intervention_name>
    <description>Use during chronic dialysis 3x/week</description>
    <arm_group_label>pre-dilution oHDF with citrate dialysate</arm_group_label>
    <arm_group_label>HD treated with citrate dialysate</arm_group_label>
    <arm_group_label>post-dilution oHDF with citrate dialysate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard dialysate (StDi)</intervention_name>
    <description>Use during chronic dialysis 3x/week</description>
    <arm_group_label>HD treated with standard dialysate</arm_group_label>
    <arm_group_label>post-dilution oHDF with standard dialysate</arm_group_label>
    <arm_group_label>pre-dilution oHDF with standard dialysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  patients of either sex aged ≥ 18 years

          -  stable chronic dialysis patients undergoing a 3x/week high-flux dialysis for at least
             three months

          -  patients without planned or predictable changes within diet, anticoagulation and
             medication regimen

        Exclusion Criteria:

          -  pregnancy or lactation or woman in child bearing age without effective contraception

          -  planned surgeries or hospital stay within the next 9 weeks

          -  use of catheter as vascular access for dialysis

          -  severe comorbidities not allowing to follow the study protocol

          -  concomitant participation in another study

          -  previous participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schmitz, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Städt. Klinikum Solingen gemeinnützige GmbH Klinik für Nephrologie und Allgemeine Innere Medizin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olaf Loke, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrologische Gemeinschaftspraxis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Kalb, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Märkische Dialysezentren GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernhard Fach, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PHV Dialysezentrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Märkische Dialysezentren GmbH</name>
      <address>
        <city>Lüdenscheid</city>
        <zip>58509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologische Gemeinschaftspraxis</name>
      <address>
        <city>Lüdenscheid</city>
        <zip>58509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Klinikum Solingen gemeinnützige GmbH Klinik für Nephrologie und Allgemeine Innere Medizin</name>
      <address>
        <city>Solingen</city>
        <zip>42653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHV Dialysezentrum</name>
      <address>
        <city>Wetzlar</city>
        <zip>35578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2011</study_first_submitted>
  <study_first_submitted_qc>February 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2012</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>citrate dialysate</keyword>
  <keyword>dialysis</keyword>
  <keyword>calcium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

